How Eric Lefkofsky Has Helped People Through His Entrepreneurship And Philanthropy

Eric Lefkofsky is a 47-year-old entrepreneur who has been heavily involved throughout his career in technology and founding new companies. He founded his first company, InnerWorkings, in May 2001 which developed into a leader in the global print manager industry. After successfully launching this company, which today serves more than 6,000 customers around the globe, he left in order to found another company in 2005 called Echo Global Logistics. This company provides supply chain and transportation management systems to businesses including those in the retail, manufacturing, and construction trades.While Eric Lefkofsky has founded other companies, so far he is probably best known for launching Groupon as a co-founder. This site connects consumers to great deals in their local community. He co-founded this company in 2007 and continues to serve as the company’s Chairman of the Board. Groupon, like all of his companies, is headquartered in his hometown of Chicago, Illinois.

It was in 2015 that Eric Lefkofsky launched what might be his most important commercial enterprise, Tempus, Inc. This company is dedicated to using technology to help patient’s around the world battle cancer. He serves as Chief Executive Officer of the company and oversees it days to day operations as well as its strategic vision and key partnerships with healthcare providers.At Tempus, Eric Lefkofsky delivers a platform that enables physicians to deliver individualized care to each patient based on their genes as well as their molecular and therapeutic data profiles. This helps doctors establish the best treatment for each patient that they will benefit from in order to cure them of their life-threatening disease.

In addition to his career dedicated to helping people, Lefkofsky also engages in philanthropy. He serves as a Trustee of a number of nonprofits including the Lurie Children’s Hospital of Chicago and the Art Institute of Chicago. Eric Lefkosky earned his bachelor’s degree at the University of Michigan. He earned a law degree from that university’s law school in 1993. Soon after graduating he was able to launch his lifelong career as an entrepreneur who seeks to improve the lives of people around the globe.

Seattle Genetics leader Clay Siegall Leads steps into finding the Cure for Cancer

Just like Silicon Valley is reputable for its cell phone, electronic and computer research, Seattle is the present cancer research center. Seattle has lately become a medical drug research hub where scientists are uniting to create the friendliest working environment. Good climate and plenty of nearby natural resources favor scientific research.

Clay Siegall’s contributions towards cancer treatment

Clay Siegall is one of the most experienced Seattle therapeutic drug and cancer research developers. He is driven by the motivation to discover cures for the many diseases that are destroying savings accounts and depleting family and company insurance funds. At the peak of his efforts to find corrective measures for cancer, Dr. Clay has shown commitment to helping all medical development aspects.

Beginning his education at the Maryland Zoology University, Dr. Clay later attained his Ph.D. from the University of George Washington. He went on to serve at the National Cancer Institute as well as the Bristol Meyers Squibb Pharmaceutical Research Institute.

He later founded his company, the Seattle Genetics where he serves as the enterprise research board director. Besides, Seattle Genetics, Dr. Clay also serves as the board director of Alder Biopharmaceuticals, Fred Hutchinson Cancer Research Business Alliance, and the American Biomedical Association.

Dr. Clay established Seattle Genetics on scientific innovation foundation, passion for helping patients as well as drug development practices. At Seattle Genetics, Dr. Clay has continuously been developing the range of products to cure cancer and other autoimmune diseases.

He has advanced antibody technology to create a unique type of antibody drugs that selectively destroys cancerous body cells. He has overseen his company’s leadership, a position that has enabled him to develop ADCs (antibody-drug conjugates) as well as the first ever brentuximab vedotin product. In partnership with the Takeda Pharmaceutical Company, Seattle Genetics has diversified into ADCs pipeline proprietary for cancer treatment.

Very often, the current cancer treatments have been too destructive and invasive. Most cancer treatments have often reduced the level of cancer cells in the body but left the human body too weak. Cancer continues to plague the society, leaving the kinds of Clay Siegall and Seattle Generics in desperate need to find cures.